Align Technology (ALGN) Q3 2026 earnings review
Align Technology cuts its sales plan as aligner prices fall
Align Technology shipped more clear aligners in the third quarter, but falling prices per case and weaker scanner sales slowed revenue growth. Total sales rose 2% from a year ago as lower overhead spending lifted operating margin excluding one-offs to 24.4%, above the company's plan. However, finance chief John Morici lowered the full-year sales outlook, and by our math the fourth-quarter plan points to a 4% sales decline from a year ago.
| Revenue | $1,014.8M +1.9% from a year ago (+2.4% at constant currency) |
|---|---|
| Clear Aligner revenue per case | $1,215 down $45 from last quarter (-2.4% from a year ago) |
| Operating margin, excluding one-offs | 24.4% above the ~24.0% plan (+0.5 percentage points from a year ago) |
| Full-year revenue outlook | Cut ~$56M now +2.1% growth at the middle of the range (vs +3–4% prior) |
⚖️ Verdict: 🔴 Bearish
The story got worse because pricing pressure and scanner leasing finally forced a cut to the full-year revenue plan. Average revenue per aligner case dropped by $45 in a single quarter, and gross margin excluding one-offs missed the company's target. On the brighter side, North American orthodontist shipments grew from a year ago for the first time in six quarters, and cost cuts kept full-year operating margin plans intact.
The question now is whether lower-priced aligner packages and leased scanners will bring in enough extra cases in 2027 to make up for the lost revenue per order. One view is that the growing base of 157,000 scanners will lift future case submissions; the other is that cheaper product tiers permanently reduce revenue per patient. Fourth-quarter revenue per case and the formal 2027 outlook will test which side is right.
🐂 Bull Case
North America Orthodontists and Dental Chains Drove Volume
Align Technology makes Invisalign clear plastic braces, which it sells through orthodontists and general dentists. North American dental clinics have ordered fewer cases for over a year, while international clinics and dental support organizations (DSOs, corporate chains that run many dental offices) carried growth. Chief executive Joe Hogan said that "for the first time in 6 quarters, orthodontist shipments in North America increased year-over-year, and DSO shipments were up double-digits, across both orthodontist and GP customers."
- Clear Aligner shipments: 690.6 thousand cases, up 6.6% from a year ago
- Doctors receiving shipments: 90,910, a third-quarter record
- Cases per active doctor: 7.6, up from 7.3 a year ago
The North American rebound helped total shipments beat the company's mid-single-digit plan even against a tougher comparison from last year. However, one quarter does not settle the long-running concern over US dental clinics, because management expects total case volume growth to slow to low single digits in the fourth quarter.
What to watch: North American doctor shipment trends on the fourth-quarter call. Another decline would show that the third-quarter pickup was only a seasonal bounce.
Tighter Overhead Spending Lifted Operating Margins
Align initiated a new round of job cuts this quarter to lower its cost base while demand stays soft. Excluding one-offs, operating margin reached 24.4%, beating the company's 24.0% target and rising 0.5 percentage points from a year ago (or 1.4 percentage points at constant currency). Hogan credited "disciplined expense management and productivity improvements" for the beat.
Lower overhead paid for the entire improvement, because gross margin excluding one-offs was flat from a year ago. Sales, general and administrative expenses (advertising, sales reps and corporate overhead) fell by 1.5 percentage points of revenue to 40.5%. The medical device maker held its full-year operating margin target of 23.7% excluding one-offs and still expects another 1.0 percentage point gain in 2027.
What to watch: fourth-quarter operating margin excluding one-offs against the 26.0% target. Hitting that mark while revenue falls from a year ago would prove that cost cuts can protect profit without sales growth.
Buybacks Rise to Top of Range as Plan Finishes
Last quarter, Align raised its full-year share buyback plan to $400–500 million alongside an operating review. During the third quarter, the orthodontic device maker bought back 627.3 thousand shares for $103.3 million by our math, at an average price of $164.73, and finished its $200 million April repurchase tranche in October.
Management now plans to buy back up to $300 million of stock in the fourth quarter, taking the full-year total to about $500 million, the top of its prior range. That lowered the diluted share count by 1.9% from a year ago to 71.0 million, which helped lift profit per share excluding one-offs by 7.3% even though net income excluding one-offs rose 5.2%.
What to watch: US cash balances and credit line usage in the quarterly filing. Last quarter, the company held $241.1 million of its cash in the US, so funding a $300 million fourth-quarter buyback may require bringing cash home from abroad or borrowing.
🐻 Bear Case
Lower Aligner Prices and Scanner Leases Cut the Plan
Align has pushed lower-priced aligner tiers — such as packages with fewer follow-up trays — and international expansion to keep case volumes growing. Those cheaper packages and faster growth in lower-priced countries reduce average selling price (ASP), the revenue Align collects per case shipped. In the third quarter, revenue per case fell to $1,215, down $45 from last quarter and down 2.4% from a year ago by our math.
- Clear Aligner revenue: $839.3 million, up 4.2% from a year ago on 6.6% case growth
- Full-year revenue outlook: cut to $4,110–4,130 million (up 2.1% by our math, vs 3–4% prior)
- Fourth-quarter revenue outlook: $1,000–1,020 million, down 3.6% from a year ago at the middle of the range by our math
Hogan said third-quarter results demonstrated "continued Clear Aligner growth", but the price drop and lower scanner sales forced management to cut the full-year revenue plan by about $56 million at the middle of the range by our math. For the fourth quarter, the company's outlook implies Clear Aligner revenue will fall 0.4% from a year ago as volume growth slows to low single digits and price per case drops another 1%.
What to watch: Clear Aligner revenue per case in the fourth quarter. A drop larger than the planned 1% decline from a year ago would show that cheaper product tiers are eroding revenue faster than new cases can replace it.
Non-GAAP Gross Margin Missed Without One-Off Cost Credits
In the first half of 2026, Align's gross margin — profit left after the cost of making and shipping its products — rose with the help of tariff refunds and warranty accounting credits in cost of goods. For the third quarter, the company had targeted a gross margin excluding one-offs of about 71.0%.
Actual gross margin excluding one-offs landed at 70.4%, missing the plan by 0.6 percentage points and dropping 1.9 percentage points from last quarter. Hogan said the miss came from "reflecting higher fuel-related transportation costs, lower Clear Aligner ASPs and geographic and product mix." In addition, the release's full-year outlook dropped the prior target for full-year gross margin excluding one-offs to rise by 1.0 percentage point to about 71.8%.
What to watch: fourth-quarter gross margin excluding one-offs against the 72.0% outlook. Another miss would confirm that lower aligner prices are weighing on manufacturing margins once one-time cost credits fade.
Scanner Placements Grow While Segment Sales Keep Falling
Align sells iTero intraoral scanners — digital wands dentists use to map a patient's teeth — and exocad design software in its Imaging Systems and CAD/CAM Services segment. Supporters view scanner placements as a funnel that leads dentists to submit more Invisalign cases later. Hogan noted that "scanner units placed—including leased, rented and certified pre-owned systems increased double-digits year-over-year, to more than 157,000 systems globally."
Because dentists are choosing leases, rentals and cheaper refurbished wands instead of buying new machines upfront, segment revenue fell 7.6% from a year ago to $175.5 million. Management cut its full-year segment outlook to $715–725 million (down 8.8% at the middle of the range by our math, worse than the prior 6–8% drop), and its fourth-quarter plan points to a 16.4% drop from a year ago.
What to watch: fourth-quarter Systems and Services revenue against the $170–180 million plan. A figure below that range would show that dental clinics are still pulling back on equipment spending.
Risks this quarter didn't answer
Several standing legal, tax and accounting concerns either stayed open or await the full quarterly filing.
- UK value-added tax dispute: Align booked another $5.6 million charge this quarter on top of $37.5 million last quarter; whether the 20% tax added to UK invoices in September hurt demand will show in regional filing disclosures.
- Recurring one-time charges: the company excluded $28.5 million of restructuring costs and $6.6 million of legal and tax charges from its preferred profit metrics in the third quarter, and plans another $7–9 million of severance and lease charges in the fourth quarter.
- Patent disputes and customer investments: rulings on competitor Angelalign and updates on Align's equity and note investments in dental chains are not in the release and await the quarterly filing.
👓 Other Themes
Weak Dental Spending Weighs on Year-End Demand
Finance chief John Morici said demand across the dental industry continued to feel pressure from "a softer environment for discretionary healthcare spending and capital equipment investment" through the third quarter. Currency movements also reduced third-quarter revenue by $5.0 million (0.5%) from a year ago. Morici said the company's early planning for 2027 revenue and margin growth assumes the economy stays soft and does not rely on a consumer rebound.
💲 Other KPIs
Current deferred revenue — cash collected upfront for aligner packages that will be recognized as future trays ship — fell for an eighth straight quarter. The balance dropped 10.2% from a year ago and $25.1 million from last quarter by our math, as doctors order more packages that include fewer follow-up trays and therefore recognize revenue immediately.
Cash generated from operations was $526.7 million for the first nine months of 2026, up 42.3% from a year ago. Subtracting first-half cash flow leaves $182.9 million for the third quarter by our math, down 3.1% from $188.7 million a year ago and down from $192.8 million in the second quarter.
Money owed by customers rose 5.9% from a year ago and 1.3% from last quarter by our math, growing faster than the 1.9% rise in third-quarter revenue. Since the end of 2025, receivables have increased by $62.1 million while quarterly sales have declined.
🔮 Guidance
Cut against what the prior full-year plan implied. The middle of the range ($1,010 million) points to a 3.6% decline from a year ago and a 0.5% dip from the third quarter by our math, missing the $1,060–1,080 million that the prior full-year outlook left for the fourth quarter.
New. Volume growth slows from 6.6% in the third quarter to low single digits in the fourth quarter against a tough 7.7% comparison from a year ago. Price per case is planned down about 1% from last year's $1,240, which implies a slight bounce from the third quarter's $1,215.
New. At the $175 million middle of the range, scanner and software revenue would stay flat from the third quarter and drop 16.4% from $209.4 million a year ago by our math, missing the typical fourth-quarter equipment buying surge.
New. The dental device maker plans for gross margin excluding one-offs to rebound 1.6 percentage points from the third quarter to 72.0%, matching the fourth quarter of 2025. GAAP gross margin includes about $2 million of contract termination costs.
New. Operating margin excluding one-offs is planned to rise 1.6 percentage points from the third quarter to 26.0%, nearly matching the 26.1% recorded a year ago despite lower revenue. GAAP margin includes $7–9 million of severance and lease exit costs.
Cut. After holding the 3–4% growth plan for three quarters, management lowered the full-year outlook to $4,110–4,130 million, or 2.1% growth at the middle of the range by our math — a reduction of about $56 million.
Trimmed. Case volume growth was widened from about 6% to 5–6%, and the price per case outlook moved from "flat to slightly down" to "slightly down" after third-quarter prices dropped to $1,215.
Cut. The new dollar range equates to an 8.8% drop from 2025 at the middle of the range by our math, worse than the 6–8% decline guided last quarter and down from the 3–4% growth expected at the start of the year.
GAAP raised; excluding one-offs unchanged. The GAAP target moved up on lower third-quarter restructuring charges, while the 23.7% target excluding one-offs (+1.0 percentage point from 2025) held for a fourth straight quarter. Management also kept its goal for ~1.0 percentage point of margin expansion in 2027.
Buybacks moved to the top of the range; capital spending unchanged. Management now plans to spend about $500 million on share repurchases this year, including up to $300 million in the fourth quarter.
❓ Key Questions
Why did full-year gross margin disappear from the outlook?
Last quarter's plan called for 2026 gross margin excluding one-offs to rise about 1.0 percentage point to roughly 71.8%. After third-quarter gross margin missed at 70.4%, the full-year gross margin line was omitted from the outlook.
What drove the $45 drop in price per case?
Clear Aligner revenue per case dropped 3.6% in a single quarter to $1,215, even though currency hurt Clear Aligner revenue by only 0.5%. How much came from cheaper product tiers versus country mix or discounts?
How will Align fund the $300 million fourth-quarter buyback?
As of June, only $241.1 million of the company's cash sat in the United States. Will the fourth-quarter repurchase require repatriating foreign cash or drawing on the $300 million credit line?
Did the 20% UK tax addition hurt British volume?
Align began adding 20% value-added tax to UK aligner invoices on September 7 and booked another $5.6 million charge this quarter. Did British doctors slow their orders in September and October?